

## **Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis**

### **Supplementary Materials**

**Supplementary Table 1: Baseline characteristics of randomized–controlled trials (RCTs) included in the meta-analysis ( $n = 42510$ ). See [Supplementary\\_Table\\_1](#)**

**Supplementary Table 2: Stratified analysis of incidence and RRs of high-grade hypertension and proteinuria for cancer patients treated with bevacizumab. See [Supplementary\\_Table\\_2](#)**

**Supplementary Table 3: Stratified analysis of incidence and RRs of all-grade hypertension and proteinuria for cancer patients treated with bevacizumab. See [Supplementary\\_Table\\_3](#)**